Arkos Global Advisors’s Health Catalyst HCAT Stock Holding History

Arkos Global Advisors’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,772	Closed	-$2K	–	159
2026 Q1	$2K	Buy	+1,772	New	+$3.33K	﹤0.01%	199

Other funds holding HCAT

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

CDC Financial Chicago, Illinois $239M AUM

PVM

Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arkos Global Advisors's HCAT Position: Q2 2026 in Review

Arkos Global Advisors sold out of Health Catalyst (HCAT) in Q2 2026, closing a stake of 1,772 shares — an estimated $2K sold.

Arkos Global Advisors first reported a position in HCAT in Q1 2026 and held it in 1 quarter. The position peaked at $2K in Q1 2026. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

Arkos Global Advisors reported no remaining Health Catalyst position as of Q2 2026 after selling out during the quarter.
Arkos Global Advisors sold 1,772 Health Catalyst shares in Q2 2026, an estimated $2K.
Arkos Global Advisors first reported a position in Health Catalyst in Q1 2026 and held it in 1 quarter.
Arkos Global Advisors's Health Catalyst position peaked at $2K in Q1 2026.
127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Arkos Global Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.